financetom
Business
financetom
/
Business
/
Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Qiagen Q1 Adjusted Earnings, Sales Decline; Q2 Outlook Issued, 2024 Guidance Affirms -- Shares Fall After Hours
Apr 29, 2024 2:11 PM

04:48 PM EDT, 04/29/2024 (MT Newswires) -- Qiagen ( QGEN ) reported Q1 adjusted earnings Monday of $0.46 per diluted share, down from $0.51 per share a year earlier.

Analysts polled by Capital IQ expected $0.44.

Net sales for the quarter ended March 31 declined to $458.8 million from $485.4 million a year earlier. Analysts surveyed by Capital IQ expected $456.9 million.

For Q2, the company expects adjusted EPS of at least $0.52 at constant exchange rates on net sales of at least $495 million. Analysts polled by Capital IQ expect adjusted earnings of $0.52 on revenue of $501.1 million.

For 2024, Qiagen ( QGEN ) reiterated its outlook of adjusted EPS of at least $2.10 and net sales of at least $2 billion. Analysts expect normalized EPS of $2.11 on revenue of $2.01 billion.

Qiagen ( QGEN ) shares fell nearly 8% in after-hours activity.

Price: 39.00, Change: -3.30, Percent Change: -7.80

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Regenxbio Signs Royalty Deal Worth Up to $250 Million With Healthcare Royalty
Regenxbio Signs Royalty Deal Worth Up to $250 Million With Healthcare Royalty
May 26, 2025
04:59 PM EDT, 05/19/2025 (MT Newswires) -- Regenxbio ( RGNX ) said Monday it closed a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare Royalty in exchange for rights to anticipated royalty payments from the sales of certain therapies. The company received $150 million at closing, extending its expected cash runway into early 2027. Healthcare...
Atlassian Insider Sold Shares Worth $1,759,739, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,759,739, According to a Recent SEC Filing
May 26, 2025
04:57 PM EDT, 05/19/2025 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, CEO, Co-Founder, on May 16, 2025, sold 7,948 shares in Atlassian ( TEAM ) for $1,759,739. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 111,272 Class A common shares of the company, with 111,272 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218025004000/xslF345X05/primarydocument.xml ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Atlassian Insider Sold Shares Worth $1,759,738, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,759,738, According to a Recent SEC Filing
May 26, 2025
04:58 PM EDT, 05/19/2025 (MT Newswires) -- Scott Farquhar, 10% Owner, Director, on May 16, 2025, sold 7,948 shares in Atlassian ( TEAM ) for $1,759,738. Following the Form 4 filing with the SEC, Farquhar has control over a total of 111,272 Class A common shares of the company, with 111,272 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218025003999/xslF345X05/primarydocument.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved